Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

30-Month Stay Disputed In Endo’s Lidoderm Litigation With Mylan

Executive Summary

Endo’s lawsuit challenging the sufficiency of Mylan’s Paragraph IV notice was thrown out in its entirety. Mylan objects to Endo’s bid to amend its complaint, saying the brand company cannot now seek to invoke a 30-month stay.

You may also be interested in...



Clinical Trials Not Required For Lidoderm Generics, FDA Tells Endo

The agency distinguishes the lidocaine pain patch from topical dermatological drugs intended to treat skin diseases in rejecting Endo’s call that ANDA sponsors demonstrate bioequivalence through clinical trials, rather than merely pharmacokinetic studies.

Watson’s Generic Lidoderm Approval Leaves Questions About Exclusivity

FDA will not decide whether the first-filer is entitled to 180 days of marketing protection until another ANDA is ready for full approval. Watson “believes” it holds marketing exclusivity for Endo’s pain patch even though it failed to obtain tentative approval within the statutory 30-month timeframe.

Biosimilars: US FDA Considering ‘Guardrails’ To Prevent Misinformation

Agency wants to ensure patients ‘aren’t unnecessarily or unfairly scared off or intimidated’ from taking biosimilars, Office of Therapeutic Biologics and Biosimilars' acting policy director Eva Temkin tells the FDA/CMS Summit; Temkin says recent guidance on biosimilar insulins shows agency is trying to be flexible on interchangeability data requirements.


Topics

Related Companies

UsernamePublicRestriction

Register

PS054703

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel